New data reveals Roche’s OCREVUS is highly effective for RRMS
Swiss pharma giant Roche announced today new data that demonstrates OCREVUS® (ocrelizumab) is a highly effective treatment option for people
Read more
monoclonal antibodies
Lilly starts Phase 3 Trial of monoclonal antibody for COVID-19 prevention
Eli Lilly and Company announced the start of BLAZE-2, a Phase 3 study of the monoclonal antibody LY-CoV555 vaccine candidate
Read more
Merck to licence two preclinical immuno oncology programs from F-star
Two additional preclinical discovery programs will be added to the Merck KGaA and F-star Therapeutics collaboration. Merck KGaA, Darmstadt, Germany
Read more
BioMed Raises $177M to Accelerate Next-Gen Biologics Development
Harbour BioMed, a global clinical stage biopharmaceutical company developing novel therapeutics in the fields of immuno-oncology, immunologic diseases, and COVID-19,
Read more
AbbVie and BioMed to develop monoclonal antibody for COVID-19
AbbVie, Harbour BioMed, Utrecht University and the Erasmus Medical Center (EMC) revealed today they have entered into a partnership to
Read more
Preventative approaches and treatment options for COVID-19
Researchers across the world are racing to develop preventative approaches and treatment options for COVID-19, including monoclonal antibodies, vaccines and
Read more
BioMed, Utrecht University and Erasmus discover antibody blocking SARS-CoV-2 in cells
Scientists at clinical-stage biopharmaceutical company Harbour BioMed (HBM), Utrecht University and Erasmus Medical Center announced that they have discovered a
Read more
Roche’s OCREVUS (ocrelizumab) can half risk of MS impairment advance
New post-hoc analysis of six years of study data for Roche’s OCREVUS (ocrelizumab) shows earlier treatment initiation nearly halves the
Read more
Altasciences completes Gimsilumab Phase I study for ARDS in COVID-19
Canadian Altasciences completes its Phase I study on Gimsilumab to prevent and treat acute respiratory distress syndrome (ARDS) in COVID-19
Read more
EC secures €37.5 million for COVID-19 vaccine development
The European Commission (EC) received an additional €37.5 million for urgent work on COVID-19 vaccine development, treatment and diagnostics. This
Read more